About 24 results found for searched term "DAPT" (0.122 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1746 | DAPT | Gamma-secretase/Beta-secretase |
| GSI-IX | ||
| DAPT (GSI-IX) is a γ-secretase inhibitor with IC50 values of 115 and 200 nM for total Aβ and Aβ42 respectively. DAPT inhibits the activation of Notch 1 signaling. | ||
| M1938 | Daptomycin | Antibiotic |
| Cubicin; Dapcin; LY146032 | ||
| Daptomycin is the first member of a new class of bactericidal antibiotics, the cyclic lipopeptides. | ||
| M6406 | Adaptaquin | Others |
| Adaptaquin is a hIF-prolyl hydroxylase-2 (PHD2) inhibitor; antioxidant. | ||
| M20858 | DAPTA | CCR |
| D-Ala-peptide T-amide, peptide T | ||
| DAPTA is a water soluble potent, selective CCR5 inhibitor which potently inhibits specific CD4-dependent binding of gp120 Bal (IC50 = 0.06 nM) and CM235 (IC50 = 0.32 nM) to CCR5. | ||
| M4529 | Rosavin | Others |
| Rosavin comes from R. Rosea. Rosavin has shown antidepressant, adaptogenic and antianxiety - like effects in mouse models. | ||
| M5062 | Polyinosinic:polycytidylic acid | TLR |
| poly I:C; Poly (I:C) | ||
| Polyinosinic:polycytidylic acid (poly I:C) is a synthetic polyinosinic-polycytidylic acid double-stranded RNA. Polyinosinic-polycytidylic acid (Poly (I:C)) is an agonist of toll-like receptor (TLR)-3. Polyinosinic-polycytidylic acid has protective effects against cerebral ischemia/reperfusion (I/R) injury and can be used as vaccine adjuvant to enhance innate and adaptive immune responses. | ||
| M8767 | MIND4-17 | Others |
| MIND4-17 is a potent NRF2 (nuclear factor erythroid 2-related factor 2) activator that covalently modifies a critical stress-sensor cysteine (C151) in the BTB domain of the E3 ligase substrate adaptor protein Kelch-like ECH-associated protein 1 (KEAP1), the primary negative regulator of NRF2. | ||
| M9602 | Atamparib (RBN-2397) | PARP |
| Atamparib | ||
| Atamparib (RBN-2397) is a potent, orally active NAD+ competitive PARP7 inhibitor with an IC50 value of less than 3 nM. Atamparib (RBN-2397) can directly inhibit cell proliferation and restore type I interferon signaling by inhibiting PARP7 in tumor cells to stimulate innate or adaptive antitumor immune responses. | ||
| M11026 | CU-T12-9 | TLR |
| Cu-t12-9 is a specific TLR1/2 agonist with EC50 of 52.9 nM. Cu-t12-9 activates both the innate and adaptive immune systems. | ||
| M14658 | Barbadin | Apoptosis |
| Barbadin is a novel and selective β-arrestin/β2-adaptin interaction inhibitor, has IC50 values of 19.1 μM for β-arrestin1 and 15.6 μM for β-arrestin2. | ||
| M24900 | Orilanolimab | Others |
| SYNT001; ALXN1830 | ||
| Orilanolimab (SYNT001) is a humanized, de-immunized and FcRn-blocking monoclonal antibody. Orilanolimab blocks the interaction between FcRn and the Fc portion of IgG molecules. Orilanolimab impedes IgG IC activation of the FcRn-mediated adaptive immune function. And Orilanolimab disrupts the associated pathways related to IgG homeostasis and innate and adaptive immunity. | ||
| M25047 | Sabatolimab | Others |
| MBG453 | ||
| Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells. | ||
| M25119 | Botensilimab | Others |
| AGEN 1181 | ||
| Botensilimab (AGEN 1181), a humanized anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) monoclonal antibody, is an innate and adaptive immune activator. Botensilimab can be used for the research of cancer. | ||
| M28487 | LP-935509 | AAK1 |
| LP-935509 is an orally active, potent, selective, ATP-competitive and brain-penetrant inhibitor of adaptor protein-2 associated kinase 1 (AAK1) with an IC50 of 3.3 nM and a Ki of 0.9 nM, respectively. LP-935509 is also a potent inhibitor of BIKE (IC50=14 nM) and a modest inhibitor of GAK (IC50=320 nM). LP-935509 shows antinociceptive activity. LP-935509 can be used for neuropathic pain and SARS-CoV-2 research. | ||
| M28593 | BMT-090605 | AAK1 |
| BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain. | ||
| M28772 | BMS-911172 | AAK1 |
| BMS-911172 is an adaptor associated kinase 1 (AAK1 kinase) inhibitor (IC50 = 35 nM). | ||
| M29394 | BMT-090605 hydrochloride | CDK |
| BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain. | ||
| M31031 | Apraglutide TFA | GLP Receptor |
| FE 203799 TFA | ||
| Apraglutide TFA (FE 203799 TFA), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum. | ||
| M31380 | Recombinant Human HSP70 Protein (HEK293, N-His) | Cytokines and Growth Factors |
| HSP70-2; HSP72; HSPA1 | ||
| HSP70 can serve a cytokine function to initiate both innate and adaptive immunity through activation of APC. HSP serves also a chaperone function and facilitates the presentation of antigen peptide to T cells. | ||
| M51624 | Protein Kinase C Peptide Substrate | Others |
| Protein Kinase C Peptide Substrate is targeted to a specific cellular compartment in a manner dependent on second messengers and on specific adapter proteins. | ||
| M58183 | Recombinant Mouse IL-15 (E. coli, N-His) | Cytokines and Growth Factors |
| interleukin 15 | ||
| Interleukin-15 (IL-15) is a 14-15 kDa glycoprotein with immune regulatory functions in many diverse cell types. As a pleiotropic cytokine, IL-15 mediates the crosstalk between innate immunity and adaptive immunity whose principal role is to kill virally infected cells. IL-15 plays a crucial role in the development, differentiation, and survival of NK cells. | ||
| M58317 | Pepinh-TRIF TFA | TLR |
| Pepinh-TRIF TFA blocks TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling by interfering with TLR-TRIF interaction. | ||
| M58535 | Recombinant Human CD5L Protein (HEK293, C-6His) | Cytokines and Growth Factors |
| CD5 Antigen-Like; CT-2 | ||
| CD5 Antigen-Like (CD5L) is a soluble protein that belongs to group B of the scavenger receptor cysteine-rich (SRCR) superfamily. CD5L regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. It binds to myelomonocytic and lymphoid cells and may play an important role in the regulation of the innate and adaptive immune systems. CD5L functions as a pattern recognition molecule by binding both lipoteichoic acid (LTA) on Gram positive and lipopolysaccharide (LPS) on Gram-negative bacteria and the SRCR domain one of CD5L retains both the LPS and LTA binding activities. | ||
| M58536 | Recombinant Mouse CD5L Protein (HEK293, C-6His) | Cytokines and Growth Factors |
| CD5 Antigen-Like; CT-2 | ||
| CD5 Antigen-Like (CD5L) is a soluble protein that belongs to group B of the scavenger receptor cysteine-rich (SRCR) superfamily. CD5L regulates mechanisms in inflammatory responses, such as infection or atherosclerosis. It binds to myelomonocytic and lymphoid cells and may play an important role in the regulation of the innate and adaptive immune systems. CD5L functions as a pattern recognition molecule by binding both lipoteichoic acid (LTA) on Gram positive and lipopolysaccharide (LPS) on Gram-negative bacteria and the SRCR domain one of CD5L retains both the LPS and LTA binding activities. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
